Welcome to our dedicated page for Rezolute SEC filings (Ticker: RZLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rezolute, Inc. filings document regulatory disclosures for a Nasdaq-listed Nevada biopharmaceutical company developing ersodetug for hyperinsulinism. Recent Current Reports on Form 8-K include Regulation FD disclosures on the sunRIZE congenital hyperinsulinism program, FDA meeting updates, investor presentations, expanded access data in tumor hyperinsulinism, and exhibits containing related press releases and corporate materials.
The filing record also includes Form 8-K disclosures for quarterly financial results, annual stockholder voting matters, board elections and amendments to executive employment agreements. These documents record the company’s clinical-development communications, governance actions, capital-market disclosures and material corporate agreements.
Rezolute, Inc. Chief Financial Officer Daron Evans reported open-market purchases of company stock. On December 15, 2025, he bought 40,000 common shares at a weighted average price of $1.766, in transactions within a range of $1.65 to $1.81. He also reported purchases of 2,500 shares each for two minor children at weighted average prices of $1.785 and $1.79.
Following these transactions, Evans directly owns 415,900 common shares. He also reports indirect beneficial ownership of shares held for three minor children, his spouse, and 40,000 shares held by PoC Capital LLC, a California limited liability company he manages, while disclaiming beneficial ownership of those LLC-held shares beyond his pecuniary interest.
Rezolute, Inc. CEO and director Nevan C. Elam reported purchasing 32,000 common shares of Rezolute on 12/15/2025 at $1.59 per share. Following this transaction, his direct beneficial ownership increased to 641,119 Rezolute common shares.
Rezolute, Inc. insider Sunil Patilal Karnawat, the company’s Chief Commercial Officer, reported open-market purchases of common stock. On 12/15/2025, he bought 12,000 common shares at $1.6199 per share and an additional 100 common shares at $1.6 per share. Following these transactions, he directly owns 71,542 Rezolute common shares, with another 8,000 shares held in an individual retirement account and 1,898 shares held in a health savings account.
Rezolute, Inc. (RZLT) reported an equity award to its Chief Medical Officer, Brian Kenneth Roberts, in a Form 4 filing. On 11/19/2025, he received 123,000 restricted stock units (RSUs) of Rezolute common shares at a price of $0. These RSUs vest annually over three years, with the first portion vesting on December 1, 2026.
On the same date, he was also granted an employee stock option covering 72,000 common shares at an exercise price of $10.16 per share. These options vest at a rate of 1/36th monthly beginning on December 19, 2025 and expire on 11/19/2035. After these transactions, Roberts beneficially owned 280,352 common shares directly, plus 15,500 shares held indirectly in an IRA, and 72,000 stock options.
Rezolute, Inc. (RZLT) reported an equity award to its Chief Commercial Officer. On November 19, 2025, the officer received 32,000 common shares in the form of restricted stock units, granted at a price of $0. After this transaction, the officer held 59,442 common shares directly, plus 8,000 shares in an individual retirement account and 1,898 shares in a health savings account.
The filing also shows a new employee stock option grant for 19,000 options with an exercise price of $10.16 per share, expiring on November 19, 2035. The restricted stock units vest annually over three years starting on December 1, 2026, while the options vest in equal monthly installments over 36 months beginning on December 19, 2025.
Rezolute, Inc. reported new equity awards to its CEO and director, Nevan C. Elam. On 11/19/2025, he received 317,000 common shares as restricted stock units at a price of $0, increasing his beneficial ownership to 609,119 common shares held directly.
He also received an employee stock option to buy 186,000 common shares at an exercise price of $10.16 per share. These options are exercisable through 11/19/2035. The restricted stock units vest annually over three years starting on December 1, 2026, and the options vest in equal monthly installments of 1/36 beginning on December 19, 2025.
Rezolute, Inc. executive equity grants disclosed
Rezolute, Inc. reported that its Chief Financial Officer, Daron Evans, acquired 107,000 restricted stock units of Rezolute common shares on 11/19/2025 at a stated price of $0. These restricted stock units vest annually over a three-year period, with the first portion vesting on December 1, 2026.
Following this transaction, Evans beneficially owns 375,900 Rezolute common shares directly, with additional indirect holdings through family members and PoC Capital, LLC. He also received an employee stock option grant covering 63,000 Rezolute common shares at an exercise price of $10.16 per share, vesting 1/36th monthly beginning on December 19, 2025 and expiring on November 19, 2035.
Rezolute, Inc. filed a Form S-8 to cover its Amended and Restated 2021 Equity Incentive Plan, under which an aggregate of 21,950,000 shares of common stock are available for issuance. Shareholders approved the amendment to this equity plan on November 19, 2025, expanding the pool of shares that can be granted to employees, directors and other eligible participants. The filing incorporates prior S-8 registrations for the same plan and updates the total shares that may be issued as equity compensation.
Rezolute, Inc. director reports new equity awards. On 11/19/2025, a director of Rezolute, Inc. (RZLT) received 21,000 restricted stock units at a stated price of $0, increasing the director’s beneficial ownership to 58,576 common shares. The RSUs fully vest on December 1, 2026, meaning the director will receive the underlying shares only after that date if the vesting conditions are met.
The director also received a stock option grant to buy 12,000 common shares at an exercise price of $10.16 per share. These options are exercisable until November 19, 2035 and fully vest on December 1, 2026. Both awards are reported as directly owned and reflect standard equity-based compensation for board service.
Rezolute, Inc. reported an equity award to a director. A board member received 21,000 common shares in the form of restricted stock units on November 19, 2025, recorded at a price of $0, increasing their directly held stake to 114,025 common shares after the transaction. These restricted stock units fully vest on December 1, 2026.
The director was also granted a stock option covering 12,000 common shares at an exercise price of $10.16 per share, expiring on November 19, 2035. The option grant also fully vests on December 1, 2026, aligning both equity awards to the same vesting date.